

ondine



For Immediate Release

Ondine Appoints Dr. Angelo Mariotti to Clinical Advisory Board

Vancouver, Canada – October 29, 2007 – Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) a medical technology company developing photodisinfection today announced that it has appointed Dr. Angelo Mariotti to its Clinical Advisory Board (CAB).

Dr. Mariotti is a Professor and Chair, Section of Periodontology, College of Dentistry at the Ohio State University and Adjunct Professor, Periodontics and Preventive Dentistry, at the University of Pittsburgh. He has held instructor and assistant professor positions at West Virginia University, Virginia Commonwealth University and University of Florida. He is on the editorial board and advisory board of the Journal of Periodontology, and is the editor of the Pharmacology and Therapeutics for Dentistry, 6th edition, 2008 and sits on the expert panel on Bisphosphonates, Council on Scientific Affairs of the ADA. In addition to an extensive publication list of papers, abstracts and book chapters, Dr. Mariotti lectures at both national and international conferences and has chaired key sessions at the IADR, AAP and AADR.

“We are very pleased that Dr. Mariotti has accepted our invitation to sit on Ondine’s Clinical Advisory Board,” said Carolyn Cross, President & CEO, Ondine Biopharma, “Dr. Mariotti’s background in both pharmacology and therapeutics in dentistry complement the capabilities and reputations of our other Clinical Advisory Board members. Dr. Mariotti will be an important resource to Ondine as the Company explores ways to expand the brand through the development of further applications and markets for Periowave™.”

Additional information relating to the members of the Clinical Advisory Board can be found on our website www.ondinebiopharma.com.

About Periowave™ and Photodisinfection

Periowave™ is a Photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated photosensitive compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are topically applied and lasers of appropriate wavelength and intensity are used to disinfect the treatment site. The Company’s Periowave™ photodisinfection system is currently approved in Canada for nasal eradication of pathogenic bacteria such as MRSA and the oral treatment of periodontitis, gingivitis, peri-implantitis, peri-mucositis, endodontics, and in the European Union for nasal eradication of MRSA, adult periodontitis, endodontics and peri-implantitis. The photodynamic disinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Business PLC, University College London.

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an

international office in St. Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information please contact:

Carolyn Cross
President and
Chief Executive Officer
Ondine Biopharma Corporation
(604) 669-0555
ccross@ondinebiopharma.com

Christina Bessant
Investor Relations
The Equicom Group Inc.
(416) 815-0700 ext. 269
cbessant@equicomgroup.com

Irma Gomez-Dib
Media & Investors Relations
FD International
(212) 850-5761
Irma.gomez.dib@fd.com

Nominated Adviser
Neil Johnson /
Ryan Gaffney
Canaccord Adams Ltd
+44(0)20 7050 6500